FDA authorises Aletta as first standalone robotic blood draw device for outpatient use

The authorisation introduces the first autonomous robotic system designed to perform blood collection under phlebotomist supervision, supporting outpatient services facing workforce pressures.

The US Food and Drug Administration (FDA) has granted De Novo marketing authorisation to Aletta, a standalone robotic blood draw device developed by Vitestro, for use in adults in outpatient settings under the supervision of a trained phlebotomist. The authorisation establishes a new category of AI- and imaging-enabled medical device that could help improve access to routine blood collection while maintaining human oversight.

Field	Content
Alert Type	Drug Approval
Drug Name	Aletta (Vitestro robotic blood draw device)
Indication	Standalone robotic medical device authorised to perform venous blood collection from the arm in adults in outpatient settings under the supervision of a trained phlebotomist. (U.S. Food and Drug Administration)
Therapy Area(s)	Diagnostics; Medical Devices; Digital Health
Geography	United States (FDA)
What Happened	On 19 August 2026, the FDA granted De Novo marketing authorisation to Vitestro's Aletta, the first standalone robotic device authorised to draw blood without hands-on operator intervention. The system uses near-infrared imaging and Doppler ultrasound to identify a suitable vein before autonomously applying a tourniquet, disinfecting the skin, inserting and removing the needle, changing collection tubes and applying a bandage. A trained phlebotomist must initiate each procedure, supervise the device and verify that samples have been collected correctly. One phlebotomist may oversee up to three Aletta devices simultaneously. (U.S. Food and Drug Administration)
Why It Matters	Blood collection is one of the most frequently performed medical procedures, and many healthcare providers face shortages of trained phlebotomists. Aletta introduces a regulated automation platform intended to support clinical workflows while retaining human oversight, although adoption will depend on implementation decisions by healthcare organisations rather than FDA authorisation alone. (U.S. Food and Drug Administration)
Supporting Context	The FDA based its decision on clinical evidence showing blood draw success rates comparable with, or better than, trained human phlebotomists when the device proceeded with venepuncture. The agency authorised the device through the De Novo pathway and established new special controls for future devices of this type. (U.S. Food and Drug Administration)
Key Takeaway	FDA authorisation establishes Aletta as the first standalone autonomous robotic blood draw device, creating a new regulated category for automated venepuncture technology. (U.S. Food and Drug Administration)
What to Watch	Clinical adoption across outpatient services, real-world operational performance, and whether additional autonomous blood collection systems follow through the FDA's newly established regulatory pathway. (U.S. Food and Drug Administration)
Primary Source	https://www.fda.gov/news-events/press-announcements/fda-authorizes-first-its-kind-robotic-blood-draw-device
Relevant Date	19 August 2026

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector 

• Contact us on: support@nuaxia.com